期刊文献+

长期口服托伐普坦治疗心力衰竭患者1例 被引量:1

下载PDF
导出
摘要 患者男性,35岁,因“间断活动后胸闷、气促30年,双下肢水肿2年,加重20d”入院。患者30年前于当地医院诊断为“先天性心脏病、主动脉瓣狭窄”,22年前行主动脉瓣机械瓣置换术(AVR)+右冠状动脉-主动脉根部旁路移植术,术后活动耐量正常,规律服用华法林抗凝。2年前患者劳累后出现胸闷气促、干咳,伴夜间阵发性呼吸困难及双下肢水肿,诊断为“心力衰竭”,规律口服培哚普利、倍他乐克、螺内酯、氢氯噻嗪、地高辛、华法林等药物。之后患者反复出现胸闷、气促,20d前因双下肢水肿加重,尿少,伴夜间阵发性呼吸困难及干咳就诊。既往有吸烟史,已戒烟,否认家族性遗传病史。
作者 王婷 赵连山
出处 《国际心血管病杂志》 2019年第4期250-253,共4页 International Journal of Cardiovascular Disease
  • 相关文献

参考文献3

二级参考文献20

  • 1魏宇淼,廖玉华,王国荣,孙艳香,张海燕,王朝晖,程龙献.强化利尿并高张盐水在难治性心力衰竭伴低钠血症患者中的疗效观察[J].临床内科杂志,2006,23(8):537-539. 被引量:8
  • 2魏宇淼,廖玉华,王国荣,孙艳香,张海燕,王朝晖.大剂量呋塞米持续静脉输注与单次及分次静脉注射在难治性心力衰竭治疗中的疗效观察[J].中国医院药学杂志,2006,26(10):1238-1241. 被引量:6
  • 3MHRA. Drug Safety Update. Tolvaptan (SamscaV ) : over-rapid increase in serum sodium and risk of serious neurological events[ EB/OL]. (2012-04-19) [2012-04-20]. http://www, mhra. gov. uk/Safetyinformation/DrugSafetyUpdate/CON149776.
  • 4McMurray JJ,Adamopoulos S,Anker SD,et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J,2012,33(14):1787-1847.
  • 5Yancy CW,Jessup M,Bozkurt B,et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,62(16):e147-239.
  • 6Doggrell SA. Tolvaptan (Otsuka)[J]. Curr Opin Investig Drugs,2004,5(9):977-983.
  • 7Schrier RW,Gross P,Gheorghiade M,et al. SALT Investigators. Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia[J]. N Engl J Med,2006,355(20):2099-2112.
  • 8Gheorghiade M,Konstam MA,Burnett JC,et al. Short term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure: results of the EVEREST clinical status trials[J]. JAMA,2007,297(12):1332-1343.
  • 9Kinugawa K,Imamura T,Komuro I. Experience of a vasopressin receptor antagonist,tolvaptan,under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther,2013,94(4):449-451.
  • 10Suzuki S,Yoshihisa A,Yamaki T,et al. AVCMA investigators. Vasopressin v2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure[J]. Int Heart J,2015,56(2):213-218.

共引文献21

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部